Development of a pH-sensitive functionalized metal organic framework: in vitro study for simultaneous delivery of doxorubicin and cyclophosphamide in breast cancer

Liposome/AZIF-8 Janus nanoplatforms: Promising nanocarriers for improving chemotherapeutic outcomes in breast cancer treatment

BACKGROUND

The incorporation of fascinating properties from multiple functional elements into a single nanoplatform has increasingly garnered interest as a strategy to improve the effectiveness of treatments, especially chemotherapy. Herein, we designed a multifunctional Janus nanoplatform composed of AZIF-8 and liposomes for the concurrent delivery of both hydrophobic and hydrophilic therapeutic agents to cancer cells for the first time. This hybrid nanoplatform integrates biomimetic strategies and active targeting mechanisms to enhance therapeutic efficacy.

METHODS

AZIF-8 nanoparticles encapsulating doxorubicin (DOX) and liposomes loaded with mitoxantrone (MTX) on opposite faces of a Janus nanoplatform were synthesized using one-pot and thin-film techniques, respectively. These two compartments were further combined through a microfluidic technique, then coated with 4T1 cancer cell membranes and conjugated with the AS1411 aptamer to enable effective tumor targeting. Upon confirming the physicochemical properties of the Janus nanoparticles, their cellular internalization, cytotoxicity, and mechanisms of cell death were evaluated in both AS1411-positive 4T1 cancer and AS1411-negative CHO cells. Following these in vitro studies, the anti-tumor efficacy, potential side effects, and in vivo biodistribution of the formulation were further assessed in BALB/c mice bearing breast tumors.

RESULTS

Characterization results confirmed the formation of liposome with a zeta potential of -51 mV and a size of 47.73 nm; AZIF-8 with a zeta potential of 6.49 mV and a size of 34.96 nm; and the final Janus nanoparticle formulation, stabilized with the cell membrane and aptamer, which exhibited a zeta potential of -38.23 mV and a size of 160 nm. The Janus@Membrane-Aptamer demonstrated significant anti-tumor activity with a potential for an effective cell-targeting towards 4T1 cell lines. This novel formulation offers a promising alternative for breast cancer therapy, utilizing dual targeting via cancer cell membrane and AS1411 aptamer to enhance precision and therapeutic efficacy. The simultaneous administration of MTX and DOX using a unified nanoplatform improves tumor treatment outcomes while minimizing adverse effects, owing to its dual-targeting capability. In vivo findings revealed considerable tumor suppression in BALB/c mice, with no observed complications affecting the organs, underscoring its potential as a safe and efficient cancer treatment approach.

CONCLUSION

Hence, Janus@Membrane-Aptamer might be an effective and safe nano-delivery platform for combined chemotherapy.

Folic acid-conjugated bovine serum albumin-coated selenium-ZIF-8 core/shell nanoparticles for dual target-specific drug delivery in breast cancer

Methotrexate (MTX), a frequently used chemotherapeutic agent, has limited water solubility, leading to rapid clearance even in local injections. In the present study, we developed folic acid-conjugated BSA-stabilized selenium-ZIF-8 core/shell nanoparticles for targeted delivery of MTX to combat breast cancer. FT-IR, XRD, SEM, TEM, and elemental mapping analysis confirmed the successful formation of FA-BSA@MTX@Se@ZIF-8. The developed nano-DDS had a mean diameter, polydispersity index, and zeta potential of 254.8 nm, 0.17, and - 16.5 mV, respectively. The release behavior of MTX from the nanocarriers was pH-dependent, where the cumulative release percentage at pH 5.4 was higher than at pH 7.4. BSA significantly improved the blood compatibility of nanoparticles so that after modifying their surface with BSA, the percentage of hemolysis decreased from 12.67 to 5.12%. The loading of methotrexate in BSA@Se@ZIF-8 nanoparticles reduced its IC50 on 4T1 cells from 40.29 µg/mL to 16.54 µg/mL, and by conjugating folic acid on the surface, this value even decreased to 12.27 µg/mL. In vivo evaluation of the inhibitory effect in tumor-bearing mice showed that FA-BSA@MTX@Se@ZIF-8 caused a 2.8-fold reduction in tumor volume compared to the free MTX, which is due to the anticancer effect of selenium nanoparticles, the pH sensitivity of ZIF-8, and the presence of folic acid on the surface as a targeting agent. More importantly, histological studies and animal body weight monitoring confirmed that developed nano-DDS does not have significant organ toxicity. Taking together, the incorporation of chemotherapeutics in folic acid-conjugated BSA-stabilized selenium-ZIF-8 nanoparticles may hold a significant impact in the field of future tumor management.

Exploring enzyme-immobilized MOFs and their application potential: biosensing, biocatalysis, targeted drug delivery and cancer therapy

Enzymes are indispensable in several applications including biosensing and degradation of pollutants and in the drug industry. However, adverse conditions restrict enzymes' utility in biocatalysis due to their inherent limitations. Metal-organic frameworks (MOFs), with their robust structure, offer an innovative avenue for enzyme immobilization, enhancing their resilience against harsh solvents and temperatures. This advancement is pivotal for application in bio-sensing, bio-catalysis, and specifically, targeted drug delivery in cancer therapy, where enzyme-MOF composites enable precise therapeutic localization, minimizing the side effects of traditional treatment. The adaptable nature of MOFs enhances drug biocompatibility and availability, significantly improving therapeutic outcomes. Moreover, the integration of enzyme-immobilized MOFs into bio-sensing represents a leap forward in the rapid and accurate identification of biomarkers, facilitating early diagnosis and disease monitoring. In bio-catalysis, this synergy promotes efficient and environmentally safe chemical synthesis, enhancing reaction rates and yields and broadening the scope of enzyme application in pharmaceutical and bio-fuel production. This review article explores the immobilization techniques and their biomedical applications, specifically focusing on drug delivery in cancer therapy and bio-sensing. Additionally, it addresses the challenges faced in this expanding field.

Application of dual chemotherapeutic drug delivery system based on metal-organic framework platform in enhancing tumor regression for breast cancer research

The nanomedicine system based on dual drug delivery systems (DDDs) can significantly enhance the efficacy of tumor treatment. Herein, a metal-organic framework, Zeolite imidazole salt frames 8 (ZIF-8), was successfully utilized as a carrier to load the dual chemotherapeutic drugs doxorubicin (DOX) and camptothecin (CPT), named DOX/CPT@ZIF-8 (denoted as DCZ), and their inhibitory effects on 4T1 breast cancer cells were evaluated. The study experimentally demonstrated the synergistic effects of the dual chemotherapeutic drugs within the ZIF-8 carrier and showed that the ZIF-8 nano-carrier loaded with the dual drugs exhibited stronger cytotoxicity and inhibitory effects on 4T1 breast cancer cells compared to single-drug treatment. The use of a ZIF-8-based dual chemotherapeutic drug carrier system highlighted its potential advantages in suppressing 4T1 breast cancer cells.

Targeted cancer treatment using folate-conjugated sponge-like ZIF-8 nanoparticles: a review

ZIF-8 (zeolitic imidazolate framework-8) is a potential drug delivery system because of its unique properties, which include a large surface area, a large pore capacity, a large loading capacity, and outstanding stability under physiological conditions. ZIF-8 nanoparticles may be readily functionalized with targeting ligands for the identification and absorption of particular cancer cells, enhancing the efficacy of chemotherapeutic medicines and reducing adverse effects. ZIF-8 is also pH-responsive, allowing medication release in the acidic milieu of cancer cells. Because of its tunable structure, it can be easily functionalized to design cancer-specific targeted medicines. The delivery of ZIF-8 to cancer cells can be facilitated by folic acid-conjugation. Hence, it can bind to overexpressed folate receptors on the surface of cancer cells, which holds the promise of reducing unwanted deliveries. As a result of its importance in cancer treatment, the folate-conjugated ZIF-8 was the major focus of this review.

Local dose-dense chemotherapy for triple-negative breast cancer via minimally invasive implantation of 3D printed devices

Dose-dense chemotherapy is the preferred first-line therapy for triple-negative breast cancer (TNBC), a highly aggressive disease with a poor prognosis. This treatment uses the same drug doses as conventional chemotherapy but with shorter dosing intervals, allowing for promising clinical outcomes with intensive treatment. However, the frequent systemic administration used for this treatment results in systemic toxicity and low patient compliance, limiting therapeutic efficacy and clinical benefit. Here, we report local dose-dense chemotherapy to treat TNBC by implanting 3D printed devices with time-programmed pulsatile release profiles. The implantable device can control the time between drug releases based on its internal microstructure design, which can be used to control dose density. The device is made of biodegradable materials for clinical convenience and designed for minimally invasive implantation via a trocar. Dose density variation of local chemotherapy using programmable release enhances anti-cancer effects in vitro and in vivo. Under the same dose density conditions, device-based chemotherapy shows a higher anti-cancer effect and less toxic response than intratumoral injection. We demonstrate local chemotherapy utilizing the implantable device that simulates the drug dose, number of releases, and treatment duration of the dose-dense AC (doxorubicin and cyclophosphamide) regimen preferred for TNBC treatment. Dose density modulation inhibits tumor growth, metastasis, and the expression of drug resistance-related proteins, including p-glycoprotein and breast cancer resistance protein. To the best of our knowledge, local dose-dense chemotherapy has not been reported, and our strategy can be expected to be utilized as a novel alternative to conventional therapies and improve anti-cancer efficiency.

pH-Responsive Biomaterials for the Treatment of Dental Caries-A Focussed and Critical Review

Dental caries is a common and costly multifactorial biofilm disease caused by cariogenic bacteria that ferment carbohydrates to lactic acid, demineralizing the inorganic component of teeth. Therefore, low pH (pH 4.5) is a characteristic signal of the localised carious environment, compared to a healthy oral pH range (6.8 to 7.4). The development of pH-responsive delivery systems that release antibacterial agents in response to low pH has gained attention as a targeted therapy for dental caries. Release is triggered by high levels of acidogenic species and their reduction may select for the establishment of health-associated biofilm communities. Moreover, drug efficacy can be amplified by the modification of the delivery system to target adhesion to the plaque biofilm to extend the retention time of antimicrobial agents in the oral cavity. In this review, recent developments of different pH-responsive nanocarriers and their biofilm targeting mechanisms are discussed. This review critically discusses the current state of the art and innovations in the development and use of smart delivery materials for dental caries treatment. The authors' views for the future of the field are also presented.

Hydrogen-bond super-amphiphile based drug delivery system: design, synthesis, and biological evaluation

Drug delivery systems (DDSs) show great application prospects in tumor therapy. So far, physical encapsulation and covalent grafting were the two most common strategies for the construction of DDSs. However, physical encapsulation-based DDSs usually suffered from low drug loading capacity and poor stability, and covalent grafting-based DDSs might reduce the activity of original drug, which greatly limited their clinical application. Therefore, it is of great research value to design a new DDS with high drug loading capacity, robust stability, and original drug activity. Herein, we report a super-amphiphile based drug delivery system (HBS-DDS) through self-assembly induced by hydrogen bonds between amino-substituted N-heterocycles of the 1,3,5-triazines and hydrophilic carmofur (HCFU). The resulting HBS-DDS had a high drug loading capacity (38.1%) and robust stability. In addition, the drug delivery system exhibited pH-triggered size change and release of drugs because of the pH responsiveness of hydrogen bonds. In particular, the anticancer ability test showed that the HBS-DDS could be efficiently ingested by tumor cells, and its half-maximal inhibitory concentration (IC50 = 3.53 μg mL-1) for HeLa cells was close to that of free HCFU (IC50 = 5.54 μg mL-1). The hydrogen bond-based DDS represents a potential drug delivery system in tumor therapy.